NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

SpyGlass Pharma, Inc. (SGP) Stock Analysis

SpyGlass Pharma, Inc. (SGP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SGP

$27.71

+$1.55 (+5.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SGP with… →

SGP Key Statistics

As of Oct 21, 2026
Trading
Open
$26.52
Previous Close
$26.16
Day's Range
26.04–27.73
52-Week Range
17.06–32.44
Volume
86.09K
Valuation
Market Cap
$926.84M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.51
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$39.87M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
33.45M
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
99.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

SpyGlass Pharma, Inc. (SGP) has a market capitalization of $926.84M.

In fiscal 2025, SGP reported revenue of $0.00.

SGP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$39.87M—
2024$0.00−$29.16M—
2023$0.00−$13.32M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$41.45M−$39.87M—
2024$0.00—−$27.06M−$29.16M—
2023$0.00—−$14.23M−$13.32M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values SpyGlass Pharma, Inc. (SGP) at $926.84M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 76.

Over the past 52 weeks the price has ranged from $17.06 to $32.44. The most recent close on file for SGP is $27.71, dated October 21, 2026. That is +$1.55 (+5.93%) against the previous close. The latest close sits 62.43% above that 52-week low.

Financial Health

In fiscal 2025, SpyGlass Pharma, Inc. reported revenue of $0.00. The same year closed with a net loss of $39.87M. Trailing earnings per share are −2.51.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The stored price history starts on February 6, 2026, and the total return since then is +4.96%.

Growth & Income

No dividend is on file for SGP.

So far in 2026 the total return is +4.96%.

Peer Comparison

SpyGlass Pharma, Inc. (SGP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SpyGlass Pharma, Inc. SGP $926.84M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. SpyGlass Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

Visit website →